Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 6
1990 18
1991 30
1992 45
1993 48
1994 66
1995 57
1996 96
1997 67
1998 59
1999 63
2000 58
2001 49
2002 48
2003 49
2004 39
2005 46
2006 38
2007 48
2008 44
2009 48
2010 56
2011 49
2012 30
2013 40
2014 48
2015 46
2016 34
2017 35
2018 31
2019 34
2020 38
2021 28
2022 20
2023 19
2024 38
2025 25
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,472 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders.
Stern ER, Collins KA, Bragdon LB, Eng GK, Recchia N, Coffey BJ, Leibu E, Murrough JW, Tobe RH, Iosifescu DV, Burdick KE, Goodman WK. Stern ER, et al. Am J Psychiatry. 2025 Mar 1;182(3):285-296. doi: 10.1176/appi.ajp.20240294. Epub 2025 Jan 29. Am J Psychiatry. 2025. PMID: 39876680 Free PMC article. Clinical Trial.
Longitudinal reductions in SP severity were related to decreases in right sensorimotor hubness in both groups, and to brainstem local coherence only in participants taking ondansetron. CONCLUSIONS: There was no effect of high-dose ondansetron on SP. However, when us …
Longitudinal reductions in SP severity were related to decreases in right sensorimotor hubness in both groups, and to brainstem local cohere …
The Effect of Granisetron, Ondansetron, and Meperidine in Preventing Postoperative Shivering: Controlled Clinical Trial.
Akhavanakbari G, Entezariasl M, Isazadehfar K. Akhavanakbari G, et al. Int Tinnitus J. 2024 Mar 21;27(2):160-166. doi: 10.5935/0946-5448.20230025. Int Tinnitus J. 2024. PMID: 38507630 Clinical Trial.

Two-tailed P < 0.05 was considered significant. RESULTS: In the meperidine, ondansetron, and granisetron groups, 4 (13.3%), 3 (10%), and 10 (33.3%) of patients experienced shivering during recovery, where the difference between the ondansetron and granisetron gro

…

Two-tailed P < 0.05 was considered significant. RESULTS: In the meperidine, ondansetron, and granisetron groups, 4 (13.3%), 3 (10%

…
Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial.
Peltz G, Jansson LM, Adeniyi-Jones S, Cohane C, Drover D, Shafer S, Wang M, Wu M, Govindaswami B, Jegatheesan P, Argani C, Khan S, Kraft WK. Peltz G, et al. J Perinatol. 2023 Mar;43(3):271-276. doi: 10.1038/s41372-022-01487-2. Epub 2022 Aug 27. J Perinatol. 2023. PMID: 36030327 Free PMC article. Clinical Trial.
The intervention arms were intravenous ondansetron or placebo during labor followed by a daily dose of ondansetron or placebo in infants for five days. RESULTS: Twenty-two (49%) ondansetron-treated and 26 (63%) placebo-treated infants required pharmacologic t …
The intervention arms were intravenous ondansetron or placebo during labor followed by a daily dose of ondansetron or placebo …
Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial.
Silverman RA, House SL, Meltzer AC, Hahn B, Lovato LM, Avarello J, Miller JB, Kalfus IN, Fathi R, Raday G, Plasse TF, Yan EC. Silverman RA, et al. JAMA Netw Open. 2019 Nov 1;2(11):e1914988. doi: 10.1001/jamanetworkopen.2019.14988. JAMA Netw Open. 2019. PMID: 31702802 Free PMC article. Clinical Trial.
Analyses were performed on an intent-to-treat basis and conducted from June 1, 2017, to November 1, 2017. INTERVENTION: Bimodal release ondansetron tablet containing 6 mg of immediate release ondansetron and 18 mg of a 24-hour release matrix for a total of 24 mg of …
Analyses were performed on an intent-to-treat basis and conducted from June 1, 2017, to November 1, 2017. INTERVENTION: Bimodal release o …
Comparison of Nausea and Vomiting Incidence After Laparoscopic Cholecystectomy With Pretreatment With Haloperidol and Ondansetron: A Randomization Clinical Trial Study.
Karami A, Ramadani E, Banifatemi M, Asmarian N, Fattahi Saravi Z. Karami A, et al. Surg Laparosc Endosc Percutan Tech. 2024 Apr 1;34(2):118-123. doi: 10.1097/SLE.0000000000001269. Surg Laparosc Endosc Percutan Tech. 2024. PMID: 38450649 Clinical Trial.
Therefore, we performed this study to compare the effect of ondansetron and haloperidol on nausea and vomiting after laparoscopic cholecystectomy. PATIENTS AND METHODS: In this randomized clinical trial, 60 patients candidates for elective laparoscopic cholecystectomy were …
Therefore, we performed this study to compare the effect of ondansetron and haloperidol on nausea and vomiting after laparoscopic cho …
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Baber N, Palmer JL, Frazer NM, Pritchard JF. Baber N, et al. Eur J Anaesthesiol Suppl. 1992 Nov;6:11-8. Eur J Anaesthesiol Suppl. 1992. PMID: 1425620 Review.
Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%. ...There is no evidence for effects of ondansetron on cardiac function (electrocardiogram, cardiac output, blood pressure and heart rate), and haem …
Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%. ...There is no …
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. Navari R, et al. J Clin Oncol. 1995 May;13(5):1242-8. doi: 10.1200/JCO.1995.13.5.1242. J Clin Oncol. 1995. PMID: 7738628 Clinical Trial.
PURPOSE: To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis. ...RESULTS: For all evaluations, single doses of granisetron 10 or 40 micrograms/kg we …
PURPOSE: To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effect …
A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery.
Park SK, Cho EJ. Park SK, et al. J Int Med Res. 2011;39(2):399-407. doi: 10.1177/147323001103900207. J Int Med Res. 2011. PMID: 21672343 Free article. Clinical Trial.
Patients received either palonosetron 0.075 mg (n = 45) or ondansetron 8 mg (n = 45), intravenously, immediately before induction of general anaesthesia. ...In conclusion, palonosetron 0.075 mg was more effective than ondansetron 8 mg in preventing PONV....
Patients received either palonosetron 0.075 mg (n = 45) or ondansetron 8 mg (n = 45), intravenously, immediately before induction of …
Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting Following General Anesthesia: A Randomized Clinical Trial.
Yazbeck-Karam VG, Siddik-Sayyid SM, Barakat HB, Korjian S, Aouad MT. Yazbeck-Karam VG, et al. Anesth Analg. 2017 Feb;124(2):438-444. doi: 10.1213/ANE.0000000000001723. Anesth Analg. 2017. PMID: 28002167 Clinical Trial.
One hundred twenty patients with PONV received either haloperidol 1 mg intravenously (n = 60) or ondansetron 4 mg intravenously (n = 60). RESULTS: Data from 112 patients (59 in the haloperidol group and 53 in the ondansetron group) were analyzed. ...CONCLUSIONS: Hal …
One hundred twenty patients with PONV received either haloperidol 1 mg intravenously (n = 60) or ondansetron 4 mg intravenously (n = …
Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
Charbit B, Alvarez JC, Dasque E, Abe E, Démolis JL, Funck-Brentano C. Charbit B, et al. Anesthesiology. 2008 Aug;109(2):206-12. doi: 10.1097/ALN.0b013e31817fd8c8. Anesthesiology. 2008. PMID: 18648229 Clinical Trial.
Subjects received 1 mg droperidol, 4 mg ondansetron, 1 mg droperidol plus 4 mg ondansetron, or a placebo, intravenously in a crossover design. ...There was no significant pharmacokinetic interaction between droperidol and ondansetron. CONCLUSIONS: Under contr …
Subjects received 1 mg droperidol, 4 mg ondansetron, 1 mg droperidol plus 4 mg ondansetron, or a placebo, intravenously in a c …
1,472 results